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Abstract
The development of antifilarial antibody responses is a characteristic feature of infection with filarial
parasites. It should be possible to exploit this fact to develop tools to monitor the progress of the
global program to eliminate lymphatic filariasis (LF); however, assays based on parasite extracts
suffer from a number of limitations, including the paucity of parasite material, the difficulty of assay
standardization and problems with assay specificity. In principle, assays based on recombinant filarial
antigens should address these limitations and provide useful tools for diagnosis and surveillance of
LF. The present multicenter study was designed to compare the performance of antibody assays
for filariasis based on recombinant antigens Bm14, WbSXP, and BmR1. Coded serum specimens
were distributed to five participating laboratories where assays for each antigen were conducted
in parallel. Assays based on Bm14, WbSXP, or BmR1 demonstrated good sensitivity (>90%) for
field use and none of the assays demonstrated reactivity with specimens from persons with non-
filarial helminth infections. Limitations of the assays are discussed. Well-designed field studies are
now needed to assess sampling methodology and the application of antibody testing to the
monitoring and surveillance of LF elimination programs.
Background
The exponential growth of the lymphatic filariasis elimi-
nation program has highlighted the need for tools that
can be used to monitor progress toward programmatic
endpoints (e.g. when to stop mass treatment) as well as to
conduct surveillance to detect any potential resumption
of transmission. Measurement of microfilaremia, the rec-
ognized gold standard for demonstrating the impact of
community-wide interventions, is not an optimal moni-
toring or surveillance tool because of the requirement for
nocturnal blood collection in much of the world and
because it is a relatively insensitive test for infection [1].
For Wuchereria bancrofti, assessment of antigenemia offers
the convenience of daytime testing and greater sensitivity
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than testing for microfilaremia; however, both micro-
filaremia and antigenemia develop from months to years
after exposure, reducing their utility for detection of low
levels of infection or recrudescence of transmission [2-6].
Entomologic methods can be used to monitor filarial
infection in mosquitoes and to provide point estimates of
transmission intensity; however, as infection levels
decline, it may become more difficult to collect sufficient
numbers of mosquitoes to demonstrate with confidence
that infection is absent [7]. By providing a cumulative
measure of exposure to filarial infection, antibody assays
may circumvent many of the limitations of methods
based on direct detection of the parasite, its antigens or its
DNA.
Antibody detection has served as the basis for diagnostic
assays for filariasis for many decades. The best of these
assays are sensitive for infection but are not specific, both
because they cannot distinguish current infection from
past infection or exposure to the parasite and because
there is some degree of cross-reactivity with other
helminth infections. On the positive side, prior studies
have shown that virtually all residents of filariasis-
endemic areas mount antifilarial antibody responses
within the first few years of life. Thus, prevalence rates of
antifilarial antibodies in children may be a useful index
for assessing changes in transmission of the infection
[8,9].
Antibody assays based on crude filarial extracts are limited
by cross-reactions with other nematode antigens [10].
Recombinant filarial antigens should, in principle, be
more useful as the basis of diagnostic or exposure assays
because of their greater specificity. As a first step in the
development and validation of such assays, we conducted
a multicenter evaluation of antibody-based diagnostic
assays using 3 recombinant antigens, Bm14, WbSXP and
BmR1.
Bm14 and WbSXP belong to a family of related genes that
encode proteins that are strong immunogens in many par-
asitic nematode infections [11]. SXP and Bm14 were orig-
inally isolated from cDNA libraries based on their strong
recognition by antibodies from microfilaremic persons,
and both have been developed as candidates for diagnos-
tic assays [12,13]. Assays based on detection of IgG4 anti-
bodies to Bm14 have sensitivities of 85–90% when serum
specimens from microfilaremic persons are tested [14,15].
This antigen is reported to be equally sensitive for sera
from patients infected with Brugia malayi or Wuchereria
bancrofti. Comparable results have been reported with
assays for SXP [11,16,17]. BmR1 encodes a secreted anti-
gen selected from a B. malayi cDNA library by antibody
screening [18,19]. ELISA and dipstick formats of BmR1
assays have been reported to have a sensitivity of >90%
when serum specimens from persons with B. malayi or B.
timori microfilaremia were tested [18-22].
The present study was designed to compare objectively the
performance of antibody assays for filariasis based on
recombinant antigens Bm14, WbSXP, and BmR1. We
report here the results of this multicenter evaluation.
Materials and Methods
Serum Specimens
Serum specimens from patients of known infection status
(see Table 1) were sent to the U.S. Centers for Disease
Control and Prevention (CDC). For persons with filaria-
sis, infection was diagnosed by detection of microfilariae.
Each specimen was assigned a code number and aliquot-
ted into 5 tubes (100 – 200 µl per tube). A panel of coded
serum samples was sent to each of the five participating
laboratories along with antigens and assay kits for testing.
Results were sent back to CDC for data analysis.
Assay formats
The Bm14 and BmR1 tests included in the evaluation are
based on the detection of antifilarial IgG4 antibodies. The
Bm14 assays were performed according to procedures
described by Weil et al. [15]. Three different assay formats
were used to test for BmR1: an ELISA [18], a dipstick [20]
and cassette. All were produced by Malaysian Bio-Diag-
nostics, Research, Sdn, Bhd. A rapid cassette test for IgG
antibody to WbSXP was produced by Span Diagnostics,
Ltd (Sachin, India). All participating labs followed assay
instructions provided by the assay or kit supplier.
Analysis of Results
Results of ELISA assays were determined using cut offs
defined by the assay developer. For qualitative tests, each
laboratory determined whether the appropriate band or
spot was visible. To collate results for a given assay with a
specific serum sample, a consensus result (either positive
or negative) was defined on the basis of agreement among
at least 4 of 5 labs. If only 3 of 5 labs obtained the same
result or if 3 did and one of the two remaining laborato-
ries did not obtain an interpretable result, this was consid-
ered to represent a lack of consensus (recorded as 'NC' or
no consensus in Tables 1 and 2). Only two labs used the
BmR1 cassette to test the specimens. Achieving consensus
required two identical results for this test. Inter-laboratory
agreement was assessed with Kappa coefficients, a meas-
ure of pair-wise agreement among observers making cate-
gorical judgments. For Bm14 and BmR1 ELISA,
categorical assignments of positive or negative results
were based on criteria established by the test developers.
Results
The Bm14 ELISA displayed comparable sensitivity for
both  W. bancrofti (91%) and Brugia (96%) infections,Filaria Journal 2004, 3:9 http://www.filariajournal.com/content/3/1/9
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while the other two tests performed better with specimens
from the homologous infections (Table 1). For example,
the BmR1 ELISA was positive for 100% of the samples
from Brugia patients, but displayed only modest sensitiv-
ity (45%) in terms of its performance with W. bancrofti
samples. Results were comparable for both the BmR1 dip-
stick and cassette (data not shown). Similarly, the WbSXP
assay was positive for 30 of 33 (91%) serum specimens
from W. bancrofti patients, but only 39% of Brugia cases.
BmR1 assays were remarkably specific for Wuchereria and
Brugia infections, and there was little reactivity with spec-
imens from persons with O. volvulus,  Loa loa or other
helminths (e.g. Strongyloides). The Bm14 assay, and to a
lesser extent, the WbSXP assay, appeared to function as a
'pan-filaria' assay, showing reactivity with the specimens
from persons with W. bancrofti, B. malayi, L. loa and O. vol-
vulus. None of the assays demonstrated reactivity with
specimens from persons with non-filarial helminth infec-
tions (Table 1) or with hyper-IgE syndrome (data not
shown).
When the geographic source of the serum specimens was
considered, additional heterogeneity in responsiveness
was noted. For example, although only a limited number
of specimens were available for testing, 4 of 6 serum spec-
imens from persons from India infected with B. malayi
were positive using the WbSXP cassette; however, none of
those from Indonesia were positive with this assay (Table
2).
Inter-laboratory categorical agreement for the ELISA
assays was quite good (Table 3). Rapid format tests,
though convenient, often presented problems of interpre-
tation, independent of the test. Some labs reported the
presence of weak bands or dots with control sera. This
resulted in a significant number of 'no consensus' results
(Table 1) as well as the lower kappa scores associated with
the rapid tests (Table 3).
Table 1: Sensitivity and Specificity of Antibody Assays1








W. bancrofti (n = 35)2 32/35 (91%) 30/33 (2 NC) (91%) 14/31 (4 NC) (45%) 17/30 (5NC) (56.7%)
B. malayi (n = 28)3 27/28 (96%) 7/18 (10 NC) (39%) 28/28 (100%) 27/27 (1NC) (100%)
O. volvulus (n = 20)4 11/16 (4 NC) (69%) 9/15 (5 NC) (60%) 0/20 (0%) 1/20 (5%)
Loa (n = 10)5 7/9 (1 NC) (78%) 3/7 (3 NC) (43%) 0/10 (0%) 0/9 (1 NC) (0%)
Other (incl. Strongyloides, 
Echinococcus; n = 20)6
0/19 (1 NC) (0%) 0/19 (1 NC) (0%) 0/20 (0%) 0/20 (0%)
1Specimens were collected from persons with documented infections with the listed parasites; for patients with filarial infections, microfilariae were 
detected. Abbreviations: NC, no consensus; specimens with a no consensus result were not included in the denominators for calculations.
2Geographic source of specimens provided in Table 2.
3Geographic source of specimens provided in Table 2.
4Ten specimens were from Guatemala and 10 were from Ecuador.
5Specimens were collected from patients in Benin.
6Echinococcus specimens were collected in Kenya; Strongyloides specimens were from several settings where lymphatic filariasis was not endemic.
Table 2: Regional Differences in Antigen Recognition
Infection Location (serum source) Bm14 ELISA SXP Cassette BmR1 ELISA
W. bancrofti
Cook Is. 10/10 9/9 (1 NC) 4/8 (2 NC)
PNG 9/10 9/9 (1 NC) 6/10
India 9/10 9/10 4/8 (2 NC)
Kenya 2/3 1/3 0/3
Haiti 2/2 2/2 0/2
B. malayi
Indonesia 10/10 0/5 (5 NC) 10/10
India 7/7 4/6 (1NC) 7/7
Malaysia 10/11 3/7 (4 NC) 11/11Filaria Journal 2004, 3:9 http://www.filariajournal.com/content/3/1/9
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Discussion
Assays based on Bm14, WbSXP, or BmR1 demonstrate
adequate sensitivity for field use. The Bm14 assay
appeared to function as a 'pan-filaria' assay, demonstrat-
ing antibody reactivity in the sera from patients with W.
bancrofti, B. malayi, L. loa and O. volvulus. Although this
cross reactivity makes the Bm14 assays useful for monitor-
ing either bancroftian or brugian filariasis, cross reactivity
with O. volvulus and L. loa may limit its utility in some
areas of sub-Saharan Africa. The BmR1 assays were sensi-
tive for B. malayi infection but relatively insensitive for W.
bancrofti infection. They showed excellent specificity for
Brugia and Wuchereria, with little reactivity with sera from
persons infected with other parasites, including L. loa and
O. volvulus. These results suggest that it may be useful to
study the W. bancrofti homologue of BmR1 to determine
if it is as specific for W. bancrofti as BmR1 is for Brugia.
Unfortunately, recent work suggests that this is not the
case [23].
For mapping the distribution of lymphatic filariasis, rapid
antibody tests may provide acceptable sensitivity, depend-
ing on the geographic area where the mapping is to be
done, but the potential for problems with specificity
(both in distinguishing past exposure from present infec-
tion as well as differentiating filarial from non-filarial
infection) still remains. For mapping W. bancrofti, there is
minimal value in using antibody tests instead of the anti-
gen tests that are currently used, but because there is no
antigen test for Brugia, antibody tests might be an alterna-
tive for mapping the distribution of these infections. In
Brugia-endemic areas, it will be important to demonstrate,
however, the relationship between prevalence rates for
microfilaremia and antibodies to validate the assay as a
useful tool for programmatic decisions. At this point, it is
not clear what antibody prevalence should be considered
an indication to initiate mass treatment; no attempt was
made in this study to distinguish between antibody
responses associated with active infection and those trig-
gered by exposure [24,25].
Antibody assays almost certainly will find other uses in
the context of lymphatic filariasis (LF) elimination pro-
grams. For example, antifilarial antibody tests may be sen-
sitive markers of transmission intensity or provide
evidence of ongoing exposure to filarial infection long
before the development of antigenemia or micro-
filaremia. Primates develop antibody responses to Bm14
within 4–8 weeks following B. malayi infection [26]. In a
longitudinal study in Egypt, microfilaria-negative persons
who were positive for Bm14 antibody at baseline were
more likely to be microfilaria-positive after one year than
were Bm14-negative persons [15]. Less is known about
the kinetics of antibody responses to BmR1. Since anti-
body responses provide an early indicator of infection,
assays for antifilarial antibodies should be useful for sur-
veillance following initiation of LF elimination programs.
As LF programs reach their planned end point (5 or more
years of > 80% drug coverage in targeted populations), it
will be necessary to determine whether or not transmis-
sion has been interrupted and whether mass drug admin-
istration can be stopped. Parasitologic testing, whether for
microfilaremia or antigenemia, will require testing of
thousands of persons to demonstrate that infection levels
are below 0.1%, the level established by the Global Pro-
gram as the end point for defining the elimination of LF.
Since antibody responses develop in the absence of
demonstrable infection, detecting incident antibody
responses should provide a more sensitive measure of
transmission than microfilaria or antigen detection. Chil-
dren born following the cessation of transmission should
be antibody-negative, while older children and adults
may have evidence of residual antibody reactivity
[8,9,27]. A testing strategy based on screening of children
could be exploited for ongoing surveillance in the after-
math of LF programs and may not require screening of as
many children as called for by current testing guidelines.
The absence of antibody in appropriately chosen popula-
tions would strongly suggest that transmission has been
interrupted. Additional studies are needed to test the
value of antibody testing as a tool for certifying the elimi-
nation of filariasis transmission.
Operational use of antibody assays requires far more prac-
tical experience with the assays than we now have. Of
greatest concern is the specificity of the tests employed.
For example, ELISA tests often use a statistical approach to
establish cutoff values for positive results. A test that is
99% specific will predictably have some false positive
results if large numbers of samples are tested. Further
work will be needed to establish rates of antibody positiv-
ity that exceed the number that are likely to occur by
chance. In addition, it will be necessary to develop and
validate algorithms for confirming the presence of infec-
tion or ongoing transmission in situations where low anti-
Table 3: Inter-lab Agreement for the Different Diagnostic Tests
Assay Range of Kappa statistics Mean
Bm14 ELISA 0.690 – 1.00 0.88
SXP Cassette 0.612 – 0.912 0.73
BmR1 ELISA 0.878 – 0.982 0.93
BmR1 Dipstick 0.817 – 0.965 0.87
BmR1 Cassette 0.546 – 1.00 0.80
Kappa statistics were derived from 10 pair-wise inter-lab 
comparisons.Filaria Journal 2004, 3:9 http://www.filariajournal.com/content/3/1/9
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body prevalence rates are detected. Despite these caveats,
we believe that antibody tests based on antigens like
Bm14, BmR1, and Wb-SXP will prove to be useful tools
that can be used to facilitate decision making by program
managers in the context of filariasis elimination
programs.
Competing Interests
GW, RN, and PK have relationships with companies inter-
ested in developing commercial applications of the Bm14,
BmR1 and WbSXP assays, respectively.
Authors' Contributions
GW, RN, PK, and VBL were responsible for the initial
development of the assays. All of the authors participated
in the planning of this multicenter study. DG was respon-
sible for coordinating specimen shipment and database
management. Participating labs included PL and DG from
CDC, RN from the Universiti Sains Malaysia, PK and VBL
from Anna Center for Biotechnology, CS from NIH and
GW from Washington University School of Medicine. PL
and EO were responsible for coordinating the study. PL
wrote the first draft of the manuscript, but all of the
authors participated in the editing of subsequent versions.
Acknowledgments
We thank Drs Amy Klion, Tania Supali, Chris King and R.K. Shenoy for pro-
viding serum specimens for testing Jacquelin M. Roberts for assistance with 
statistical analysis, and all of the participants in the Denver meeting for their 
valuable support. Funding for the BmR1 tests was provided by European 
Commission grant No: ICA4-CT-2001-10081 and Malaysian Bio-Diagnostic 
Research Sdn. Bhd.
References
1. Eberhard ML, Lammie PJ: Laboratory diagnosis of filariasis. Clin
Lab Med 1991, 11:977-1010.
2. Weil GJ, Jain DC, Santhanam S, Malhotra A, Kumar H, Sethumadhavan
S, Liftis F, Ghosh TK: A monoclonal antibody-based enzyme
immunoassay for detecting parasite antigenemia in Bancrof-
tian filariasis. J Infect Dis 1987, 156:350-355.
3. More SJ, Copeman DB: A highly specific and sensitive mono-
clonal antibody-based ELISA for the detection of circulating
antigen in Bancroftian filariasis.  Trop Med Parasitol 1990,
41:403-406.
4. Weil GJ, Lammie PJ, Weiss N: The ICT filariasis test: a rapid for-
mat antigen test for diagnosis of bancroftian filariasis. Parasi-
tology Today 1997, 13:401-404.
5. Lammie PJ, Reiss MD, Dimock KA, Streit TG, Roberts JM, Eberhard
ML: Longitudinal analysis of the development of filarial infec-
tion and antifilarial immunity in a cohort of Haitian children.
Am J Trop Med Hyg 1998, 59:217-221.
6. Witt C, Ottesen EA: Lymphatic filariasis: an infection of
childhood. Trop Med Int Health 2001, 6:582-606.
7. Burkot T, Ichimori K: The PacELF programme: will mass drug
administration be enough? Trends Parasitol 2002, 18:109-115.
8. Weil GJ, Steel C, Liftis F, Li B-W, Mearns G, Lobos E, Nutman TB: A
rapid-format antibody card test for diagnosis of
onchocerciasis. J Infect Dis 2000, 182:1796-1799.
9. Gao CL, Cao WC, Chen XX: Changes in anti-filarial antibody
after control of filariasis in Shandong Province. Chin Med J
(Engl) 1994, 107:360-363.
10. Maizels RM, Sutanto I, Gomez-Priego A, Lillywhite J, Denham DA:
Specificity of surface molecules of adult Brugia  parasites:
cross-reactivity with antibody from Wuchereria, Onchocerca
and other human filarial infections.  Trop Med Parasitol 1985,
36:233-237.
11. Rao KVN, Eswaran M, Ravi V, Gnanasekhar B, Narayanan RB, Kaliraj
P, Jayaraman K, Marson A, Raghavan N, Scott AL: Wuchereria ban-
crofti orthologue of Brugia malayi SXP1 and the diagnosis of
bancroftian filariasis. Mol Biochem Parasitol 2000, 107:71-80.
12. Dissanayake S, Xu M, Piessens WF: A cloned antigen for serolog-
ical diagnosis of Wuchereria bancrofti microfilaremia with
daytime blood samples. Mol Biochem Parasitol 1992, 56:269-278.
13. Chandrashekar R, Curtis KC, Ramzy RM, Liftis F, Li B-W, Weil GJ:
Molecular cloning of Brugia malayi antigens for diagnosis of
lymphatic filariasis. Mol Biochem Parasitol 1994, 64:261-271.
14. Ramzy RMR, Helmy H, Faris R, Gad AM, Chandrashekar R, Weil GJ:
Evaluation of a recombinant antigen-based antibody assay
for diagnosis of bancroftian filariasis in Egypt. Ann Trop Med
Parasitol 1995, 89:443-446.
15. Weil GJ, Ramzy RM, El Setouhy M, Kandil AM, Ahmed ES, Farris R: A
longitudinal study of bancroftian filariasis in the Nile Delta of
Egypt: baseline data and one-year follow up. Am J Trop Med Hyg
1999, 61:53-58.
16. Theodore JG, Kaliraj P, Jayachandran S, Jayaraman K: Cloning, over-
expression and evaluation of a recombinant fusion protein of
Wuchereria bancrofti toward its application as a diagnostic
agent for Bancroftian filariasis. Parasitology 1993, 106:413-420.
17. Dissanayake S, Zheng H, Dreyer G, Xu M, Watawana L, Cheng G,
Wang S, Morin P, Deng B, Kurniawan L, Vincent A, Piessens WF:
Evaluation of a recombinant parasite antigen for the diagno-
sis of lymphatic filariasis. Am J Trop Med Hyg 1994, 50:727-734.
18. Rahmah N, Lim BH, Anuar AK, Shenoy RK, Kumaraswami V, Hakim
SL, Chotechuang P, Kanjanopas K, Ramachandran CP: A recom-
binant antigen-based IgG4 ELISA for the specific and sensi-
tive detection of Brugia malayi infection. Trans Roy Soc Trop Med
Hyg 2001, 95:280-284.
19. Rahmah N, Lim BH, Azian H, Tengku Ramelah TS, Rohanna AR: Use
of a recombinant antigen-based ELISA to determine preva-
lence of brugian filariasis among Malaysian school children
near Pasir Mas, Kelantan, – Thailand border.  Trop Med Int
Health 2003, 8:158-163.
20. Rahmah N, Taniawati S, Shenoy RK, Lim BH, Kumaraswami V, Anuar
AK, Hakim SL, Hayati MIN, Chan BT, Suharni M, Ramachandran CP:
Specificity and sensitivity of a rapid dipstick test (Brugia
Rapid) in the detection of Brugia malayi infection. Trans Roy Soc
Trop Med Hyg 2001, 95:601-604.
21. Rahmah N, Shenoy RK, Nutman TB, Weiss N, Gilmour K, Maizels
RM, Yazdanbakhsh M, Sartono E: Multicentre laboratory evalua-
tion of Brugia Rapid dipstick test for detection of brugian
filariasis. Trop Med Int Health 2003, 8:895-900.
22. Supali T, Rahmah N, Djuardi Y, Sartono E, Rückert P, Fischer P:
Detection of filarial-specific IgG4 antibodies using Brugia
Rapid test in individuals from an area highly endemic for Bru-
gia timori. Acta Tropica 2004, 90:255-261.
23. Rahmah N, Ros Azeana AA, Ravindran B, Fischer P: Homologs of
the Brugia malayi diagnostic antigen BmR1 are present in
other filarial parasites, but induce different humoral
immune response. . Manuscript submitted
24. Wamae CN, Gatika SM, Roberts JM, Lammie PJ: Wuchereria ban-
crofti in Kwale District, Coastal Kenya. I. Patterns of focal
distribution of infection, clinical manifestations and antifilar-
ial IgG responsiveness. Parasitology 1998, 116:173-182.
25. Washington CH, Radday J, Streit TG, Boyd HA, Beach MJ, Addiss DG,
Lovince R, Lovegrove M, Lafontant JG, Lammie PJ, Hightower AW:
Spatial clustering of filarial transmission before and after a
mass drug administration in a setting of low infection
prevalence. Filaria J 2004, 3:3.
26. Dennis VA, Kasater BL, Lowrie RC Jr, Bakeer M, Chandrashekar R,
Weil GJ, Xu K: Antibody responses to recombinant Brugia
malayi antigens in experimentally infected Rhesus monkeys.
Am J Trop Med Hyg 1995, 53(suppl):174-175. abst
27. Rodriguez-Perez MA, Danis-Lozano R, Rodriguez MH, Bradley JE:
Comparison of serological and parasitological assessments
of Onchocerca volvulus transmission after 7 years of mass
ivermectin treatment in Mexico.  Trop Med Int Health 1999,
4:98-104.